Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? by Kirschey, Sebastian et al.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: Oncology 2012:6 153–164
doi: 10.4137/CMO.S7327
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Oncology
RevIew
Clinical Medicine Insights: Oncology 2012:6  153
Relapsed and/or Refractory Mantle cell Lymphoma:  
What Role for Temsirolimus?
Sebastian Kirschey, Susanne wagner and Georg Hess
Department of Hematology, Oncology, and Pneumology, University Medical School, Johannes Gutenberg-University, 
Langenbeckstr. 1, 55131 Mainz. Corresponding author email: georg.hess@unimedizin-mainz.de
Abstract: Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of 
the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered 
the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical 
knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown 
to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline 
of other treatment options, we aim to guide at which place in the current treatment algorithms Temsirolimus can be integrated into the 
treatment of MCL patients.
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Introduction
Mantle  Cell  Lymphoma  (MCL)  is  a  well  defined 
subtype  of  B-cell  non-Hodgkin  Lymphoma  and 
represents  5%  to  10%  of  that  entity  with  an 
incidence  of  2–3/100.000.1  It  is,  apart  from  rare 
exceptions,  characterized  by  a  chromosomal 
translocation t(11;14) (q13;q32) with nuclear cyclin 
D1  overexpression.  Typically,  MCL  occurs  in 
elderly people with a median age of 65 years and 
a  clear  predominance  of  male  patients.2  At  time 
of diagnosis, most of the patients with MCL will 
typically  show  an  already  disseminated  disease. 
The  most  common  extranodal  manifestations 
involve bone marrow, liver, spleen, the Waldeyer´s 
tonsillar ring, and the gastrointestinal tract,3 the last-
mentioned  occasionally  resulting  in  first  clinical 
symptoms.4,5 The severity of symptoms correlates 
with stage and disease dynamics. Several subtypes of 
mantle cell lymphoma with distinct disease courses 
have been established so far: an indolent subtype, 
very slow in progress and characterized by a benign 
course, is found in 10%–15% of patients. The most 
frequent subtype is the classical MCL with a medium 
rapid course, and the most aggressive variant is the 
blastoid subtype that is found in 10% of patients, 
with a frequently very dismal course. The “Mantle 
cell  Lymphoma  International  Prognostic-Index” 
(MIPI) includes four independent prognostic factors 
of  MCL  (ECOG  performance  status  .2,  white 
blood cell count .6,7/nL, LDH level .245 U/L and 
age .60 years6) and is a simple method to estimate 
the  individual  risk  associated  with  the  disease. 
By  applying  this  MIPI,  patients  can  be  stratified 
into  3  risk-groups.  Basis  for  this  stratification  is 
the prospective median overall survival (OS: time 
period  between  diagnosis  and  death  or  therapy 
initiation and death, if appropriate): low risk (OS of 
6 years), intermediate risk (OS of 4 years) and high 
risk (OS of 2 years). Despite the high response rates 
to induction therapy, cure is almost never achieved.7 
The median overall survival has been found to be not 
more than 3 to 4 years, and the proportion of long-
term survivors has been low.8 Only in recent years, 
significant therapy improvements have been achieved 
by the use of dose-intensive chemotherapy regimens 
and the introduction of monoclonal antibodies, so 
that—at least for younger patients—a median OS of 
more than 5 years can now be assumed.9,10
Therapy
Untreated MCL
The selection of appropriate therapy is an individual 
decision and depends on various parameters, particu-
larly age, performance status, MIPI, patient’s wish etc. 
A watch-and-wait strategy can only be recommended 
in asymptomatic patients with a low tumor burden 
and should otherwise not be pursued.2 Recently, how-
ever, markers like SOX11 that may help to specify at 
an early stage those patients in whom a watch-and-
wait strategy might be justified have been identified.11 
Besides the rare cases of truly limited MCL, where no 
commonly accepted standard exists, systemic therapy 
is the standard clinical option for most of the patients 
with MCL at time of diagnosis.
Currently,  different  treatment  approaches  are 
in  use:  conventional  chemoimmunotherapy,  dose-
  escalated chemoimmunotherapy and palliative care, 
using single agents for frail patients. Potential algo-
rithms for younger and elder patients are outlined in 
  Figures 1 and 2. In brief, for the treatment of younger 
patients  CHOP  (cyclophosphamide,  doxorubicin, 
vincristine,  and  prednisone)  therapy  has  been  the 
treatment of choice for a long period. While the use 
of single-agent Rituximab has shown a merely mod-
erate activity in MCL with an overall response rate of 
only 27%,12 a number of studies have by now dem-
onstrated a benefit in median progression free sur-
vival (median time from initiation of treatment and 
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Figure  1.  Schematic  overview  of  potential  treatment  approaches  – 
younger/fit patients.
Abbreviations: FL, first line; HDT, high dose therapy; SCT, stem cell 
transplantation; 2nd, second line treatment; .2nd, higher than   second 
line treatments.Temsirolimus for relapsed mantle cell lymphoma
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disease   progression) and median OS when the drug is 
  combined with chemotherapy,2,13–15 and combination 
therapies are nowadays considered standard of care.
Furthermore,  for  younger/fit  patients  dose-
  intensified treatments have been proven   beneficial. 
Two  general  strategies  are  adopted  presently: 
one  employing  dose-escalated  regimen  like 
R-  HyperCVAD  (cyclophosphamide,  vincristine, 
doxorubicin,  dexamethasone,  cytarabine,  and 
methotrexate),16 or regimen that incorporate a con-
solidative  high-dose  therapy  after  an  induction 
treatment. This  induction  frequently  consisted  of 
(R)-CHOP. Recently, however, several studies have 
been examining the effect of high-dose cytarabi-
nosid implementation.9 A randomized trial of the 
  European  Mantle  Cell    Lymphoma  Network  has 
demonstrated the superiority of a high-dose cytara-
binosid (ARA-C)-containing induction regimen like 
DHAP (dexamethasone, high-dose Ara-C, and cis-
platin) to the use of CHOP for induction, indicated 
by  a  significant  prolongation  of  progression  free 
survival. Therefore to date – at least in Europe—a 
cytarabinoid-containing  induction  followed  by 
high-dose consolidation with autologous stem cell 
transplantation represents the standard front-line-
therapy in younger patients (,65 years).2,17–19
Appropriate  combination  regimens  in  elderly 
patients  (.65years)  or  patients  with  comorbidities 
who are not qualified for dose-intensive therapy are 
the less intensive regimens like R-CHOP or, nowa-
days,  bendamustine-rituximab  (BR).  The  effect 
of  bendamustine  as  first-line  therapy  especially  in 
elderly patients with MCL has been shown in a study 
by Rummel et al with an improved complete remis-
sion (CR)-rate of 40,1% for BR versus 30,8% for 
R-CHOP and an improved PFS of 32.4 month versus 
of 22,4 month, respectively.20 Recent data support the 
use of Rituximab as maintenance therapy, at least in 
patients  receiving  conventional-dose  chemoimmu-
notherapy (Kluin-  Neelemans et al. oral presentation, 
EHA 2011). Patients that are unable to tolerate such 
an  aggressive  treatment  are  qualified  for  a  single-
agent therapy or a dose-reduced chemotherapy regi-
men with a palliative intent.17
Relapsed/Refractory MCL
For patients with relapsed disease, the choice of the 
most suitable therapy regimen depends on multiple 
parameters (Box 1), such as type of primary therapy, 
response  to  treatment,  remission  duration  etc.  For 
elderly patients or patients with long remissions to the 
last line of a chemoimmunotherapy, repetition of the 
initial or introduction of an alternative chemotherapy 
combination seems reasonable. In general, non-cross 
resistant regimens are frequently used, e.g., R-CHOP 
followed by BR or vice versa.
So  far,  allogeneic  stem  cell  transplantation  is 
the  only  curative  therapeutic  approach  in  patients 
with advanced stage MCL based on a graft-versus-
  lymphoma  effect.  But  because  of  the  considerable 
morbidity  and  mortality  associated  with  this  ther-
apy, only a subset of patients are suitable candidates 
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Figure 2. Schematic overview of potential treatment approaches – elderly/unfit 
patients.
Abbreviations: R-CHOP, rituximab, cyclophosphamid, doxorubicin, vin-
cristine, prednison; R-B, rituximab-bendamustine; FL, Firstline treatment; 
2nd, second line treatment; .2nd, higher than second line treatments.
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Box 1. Criteria for the selection of subsequent treatment.Kirschey et al
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for such an approach.18 Khouri et al reported on the 
  introduction  of  a  reduced-intensity  conditioning 
in  patients  with  relapsed  MCL. The  results  of  his 
study show a 100-day mortality of 0%, a CR-rate 
(no    clinical  evidence  of  disease  or  disease-related 
symptoms and spleen and liver non-palpable, with-
out nodules) of 94% and a 3-year progression free 
  survival (PFS:   initiation of therapy until the occur-
rence of any disease   progression or death) and median 
overall survival (OS) of 82% and 85%.18,21 Although 
no prospective data are available yet, the option of 
allogeneic stem cell transplantation should be evalu-
ated in patients with relapsed disease after appropri-
ate first-line therapy, and this especially holds true for 
young and motivated patients.
Besides these commonly proposed approaches, no 
general consensus exists on how to treat patients with 
relapsed  MCL.  Due  to  its  high  genetic  instability, 
though, success rates and remission duration rapidly 
decrease during the course of disease, and patients 
have to be considered chemotherapy-refractory. Thus, 
additional options were and are urgently needed for 
these patients.
Due to the MCL’s well-defined pathophysiology, 
determining distinct therapeutic targets, a variety of 
candidate  drugs  has  been  identified  and  clinically 
developed,  e.g.,  approaches  like  bortezomib  as  a 
proteasome inhibitor or thalidomide/lenalidomide as 
immunomodulatory agents.14,22 This review will focus 
on the results found for temsirolimus, a mTOR inhib-
itor, currently approved for the treatment of relapsed 
MCL in the EU.
mTOR-Inhibition
The mTOR pathway and pharmacologic mTOR-
inhibition
The phosphatidylinositol-3-kinase (Pi3K) is among 
the  most  frequently  affected  pathways  in  malig-
nancy. Additional members of this pathway include 
AKT, the negative regulator PTEN, and the mamma-
lian Target Of Rapamycine (mTOR). These proteins 
are  affected  in  various  tumor  entities,  especially 
malignant lymphoma.23 mTOR itself regulates the 
translation of other oncogenes, for example cyclin 
A and c/EBPβ. In all of them, an increased activa-
tion  of  mTOR  leads  to  cell  proliferation,  activa-
tion of growth and survival pathways, and inhibits 
autophagy.24
As described, in MCL an overexpression of Cyclin 
D1 results from the t(11;14). The gene (CCND1) coding 
for cyclin D1 consists of 5 exons which could be alter-
natively spliced in two different mRNAs leading to two 
different proteins: cyclin D1a and cyclin D1b.1 Cyclin 
D1a and cyclin-dependent kinases 4 and 6 (CDK 4/6) 
form a complex and thereby promote cell cycle entry. 
Both CDK4 and CDK6 are frequently overexpressed 
in patients with MCL, thereby perpetuating cell pro-
liferation.1 Although further studies have shown that 
isolated cyclin D1 overexpression is not sufficient to 
induce MCL in mice, it is considered a hallmark of dis-
ease development accompanied by additional events/
mutations.25 Cyclin D translation is mainly regulated 
via the PI3K/PTEN/Akt/mTOR pathway,26 As a con-
sequence inhibition of elements of this pathway is an 
attractive therapeutic approach to counteract the cell 
cycle driving potential of cyclin D1.
Rapamycine – the first available mTOR-inhibitor—
was  isolated  from  the  bacterium  Streptomyces 
hygroscopius  in  1970.  To  date,  rapamycine  is 
mainly used as immunosuppressive agent. However, 
already early studies have demonstrated its poten-
tial as an antitumor agent and its cytostatic proper-
ties, and it was the first molecule to inhibit the Pi3K/
AKT   pathway. Rapamycine exerts its effect on the 
cell by ligating the 12 kDa FK506-binding protein 
(FKBP12). The complex of both inhibits the activity 
of mTOR through allosteric binding.27,28 The mTOR 
protein itself acts within 2 separate multiprotein sig-
naling complexes: mTOR complex 1 (mTORC1) and 
mTOR complex 2 (mTORC2). While the rapamy-
cin-sensitive mTORC1 complex is a key element of 
numerous signaling as described above, mTORC2, 
generally perceived as rapamycine insensitive,29 is 
involved in processes like cytoskeleton reorganisa-
tion. Lately, Sarbassov et al have shown that a pro-
longed use of rapamycin also leads to an inhibition 
of mTORC2 AKT and of the PI3K/AKT pathway in 
vitro. This can be explained as a consumption of free 
mTOR molecules, and thus the resulting ability to 
bind also mTORC2.30 The activation of mTOR leads 
to a phosphorylation of downstream targets like eIF-
4EBP1 (Eukaryotic Translation Initiation Factor-4E-
Binding Protein-1) and the ribosomal protein S6K1 
(S6 Kinase 1), and this results finally in an increase 
in the translation of a subset of mRNAs that encode 
for  proteins  often  associated  with  a    proliferative Temsirolimus for relapsed mantle cell lymphoma
Clinical Medicine Insights: Oncology 2012:6  157
response and with the transition from G1 to S-phase 
of cell cycle.31,32
In vitro studies using rapamycine in several MCL 
cell lines showed a reduction of cyclinD1 and the 
antiapoptotic  proteins  cFLIP,  BCL-XL  and  Mcl-1 
by  pharmacological  inhibition  of  the  PI3K/AKT 
  pathway.33 The reduction of cyclin D1 mRNA levels 
leads to a deficiency of active CDK4/cyclin D1 com-
plexes. As rapamycine seems to affect primarily the 
stability of the transcript, a cytostatic rather than a 
cytotoxic effect was assumed.34 However, it has been 
found that some apoptotic processes are particularly 
evident in B-cells and rhabdomyosarcoma cells.35,36
In addition, mTOR inhibitors could synergize with 
other cytotoxic agents, such as vincristine, doxoru-
bicin, bortezomib or rituximab, resulting in a pro-
nounced inhibition of Raf-1, MAPK and mTOR.29 
Temsirolimus also shows a synergistic antineoplas-
tic effect in combination with vorinostat. It can be 
  presumed that the addition of this histone deacetylase 
inhibitor exerted a proapoptotic effect with induction 
of autophagy in, for example, renal cancer cells.37,38 
Autophagy could be observed in the development of 
acidic vesicular organelles.10
Clinical development of temsirolimus  
in MCL
Single agent temsirolimus
Temsirolimus is one of the mTOR–Inhibitors in clini-
cal use that are currently available (others: Everolimus, 
Ridaferolimus). It is the water-soluble ester-  derivative 
of  rapamycine.  All  mTOR  inhibitors  display  the 
same effect by binding mTOR via FKBP12 with a 
high specificity. The chemical structure of temsiroli-
mus is shown in Figure 3. In several phase-I/II stud-
ies, pharmacokinetic properties of temsirolimus have 
been evaluated for the first time. In a dose escalation 
phase I trial in patients with advanced solid tumors 
using temsirolimus in doses from 7.5 to 220 mg/m² as 
weekly 30-minute infusion, tolerability was demon-
strated over a wide dose range. Reversible thrombo-
cytopenia was noted as dose limiting toxicity (DLT) 
in this study. The most common drug-related adverse 
events were skin toxicity and mucositis/  stomatitis. No 
clinical immunosuppressive effects were observed.39 
In addition, Atkins et al also conducted a dose esca-
lation  study  in  patients  with  advanced  refractory 
renal cancer, employing 25 mg, 75 mg and 250 mg 
of   temsirolimus.40 In fact,   neither toxicity nor efficacy 
in both trials seemed to be significantly influenced by 
dose levels, and patients showed responses to treat-
ment at all dose levels.40 As the measuring of pharma-
cokinetics based on body surface failed to demonstrate 
any superiority, too, further studies were conducted 
using a flat-dosing of temsirolimus.7
Two  Phase  II  Studies  evaluated  temsirolimus 
in different doses (250 mg/25 mg once weekly) as 
single agent in patients with relapsed or refractory 
MCL. The initial trial tested temsirolimus in a dose 
of 250 mg, similarly to trials in solid tumors that were 
active at the same time. In this study, Witzig et al 
reported on 35 patients. 34 patients with a median 
age of 70 years (range, 38–89years) were evaluable 
for analysis whereof 50% showed refractory disease, 
91% had stage IV disease, in 69% 2 or more extran-
odal sites were found, with a median of 3 prior thera-
pies (range 1–11) (rituximab (89%), alkylating agent 
(94%), or anthracycline (83%)). The overall response 
rate was 38%, with one complete remission (3%) and 
12 partial remissions (35%). The median time to pro-
gression in all patients was 6.5 months (range, 2.9 
to 8.3 months), for the 13 patients with a response 
the duration of response was 6.9 months (range, 5.2 
to 12.4 months). Thrombocytopenia was one of the 
most frequent side effects and required a dose reduc-
tion in the majority of patients41 (Table 1).
As  a  consequence  of  the  observed  side  effects, 
an  additional  phase  II  study  tested  25  mg  single 
agent temsirolimus, the dose approved for renal cell 
  cancer.  Again  a  heavily  pretreated  study  popula-
tion of 29 Patients was enrolled of whom 50% were 
refractory with a lack of complete or partial remis-
sion within 1 month to the last therapy. 27 Patients 
were evaluable for the analysis. The median age was 
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Figure 3. Structure of temsirolimus.Kirschey et al
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69  years  (range,  51–85  years),  86%  had  stage  IV 
disease, 71% showed 2 or more extranodal sites, and 
all had received a median of 4 prior therapies (range, 
1–9) (rituximab (96%), alkylating agent (96%), or 
anthracycline (79%)). Similar to the initial trial’s out-
come, an overall response rate of 41% was observed 
(1 complete response (3.7%) and 10 partial responses 
(37%)).  For  all  patients,  the  median  time  to  pro-
gression was 6 months, and the median duration of 
response for the 11 responders was 6 months (range, 
1–26 months).42 Similar to the findings in other stud-
ies, primarily hematologic side effects were observed, 
and especially thrombocytopenia was the most com-
mon cause for dose reduction again.39,42
Owing  to  the  promising  results  of  the  phase  II 
trials, a randomized open label phase III study was 
performed  to  evaluate  temsirolimus  in  two  dosing 
levels compared with investigator´s choice   therapy.43 
  Altogether, 162 patients with relapsed or refractory 
MCL were included. Patients were randomly assigned 
to  three  groups  (54/54/53).  Treatment  consisted  of 
temsirolimus 175 mg once weekly for three weeks, fol-
lowed by either temsirolimus 75 mg, 25 mg weekly, or 
investigator´s choice treatment of options approved in 
advance (multiple conventional cytostatic regimes i.v. 
or p.o.; e.g., gemcitabine, fludarabine, thalidomide p.o.; 
alemtuzumab i.v.). Patients’ characteristics were well 
spread among all groups, the median age was 68 years 
(range, 44–87 years) in the temsirolimus 175/75 mg, 
68.5 years (range, 43–85 years) in the 175/25 mg and 
64.5 (range, 39–88 years) in the investigator´s choice 
cohort. The patients in the two different temsirolimus 
groups had received a median of three prior therapies 
whereas the patients in the investigator´s choice arm 
had been treated with a median of four prior therapies. 
Stage III and IV disease at baseline was 100%, 96% 
and 94% for the three groups: 175/75 mg, 175/25 mg 
and investigator´s choice, respectively (Table 2). The 
overall response rates were 22%, 6%, 2% in the three 
groups  (175/75  mg,  175/25  mg  and  investigator´s 
choice),  with  complete  remission  rates  of  2%,  0% 
and 2%. Partial remissions were induced in 20%, 6% 
and 0% of patients. The median time to progression 
(representing the primary objective of the trial) was 
4.8 months for temsirolimus 175/75 mg, 3.4 months 
for  temsirolimus  175/25  mg  and  1.9  months  for 
investigator´s choice group. This difference proved to 
be statistically significant.43
Table 1. Comparison of side effects observed in different phase II trials.
% phase II 250 mg phase II 25 mg
All grades 3° or 4° All grades 3° or 4°
Thrombocytopenia 100 66 82 39
Asthenia 66 11 75 25
Anemia 66 26 15
Diarrhea 77 11 4
Fever NR NR NR NR
Anorexia 40 3 4
Mucositis 71 6 39
Nosebleeds NR NR NR NR
erythema/rash 51 7 36
Infections 63 26 32 15
Table 2. Response according to treatment arms of the randomized phase III trial.
TeMsR 175/75  
n = 54
TeMsR 175/25  
n = 54
Invest choice   
n = 54
Overall response rate 22% 6% 2%
95% CI 11–13 0–12 0–5
P-value 0.0019 0.6179
Complete remissions, n 1 0 1
Partial remissions, n 11 3 0
Response median (95% CI), in month 7.1 (4.1–NA) 3.6 (3.2–10.6) NATemsirolimus for relapsed mantle cell lymphoma
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Apart from the observed differences in efficacy, 
pronounced  hematologic  toxicity  was  found  to  be 
associated  with  temsirolimus,  and  this  again  in  a 
dose-dependent  manner.  In  the  different  temsiroli-
mus cohorts, rates of grade 3 thrombocytopenia were 
found in 63% (grade 4 3%) in the 175/75 and 39% 
(grade 4 0%) of the patients in the 175/25 mg dose 
group, respectively. Similarly, the neutropenia rates 
were higher in the 250 mg cohort (23% of patients 
had grade 3 and 6% of patients grade 4 thrombo-
cytopenia),  as  compared  with  the  25  mg  cohort 
(18% grade 3 and 0% grade 4).41,42 The grade 3 and 
4 neutropenia rates were considerably higher in the 
investigator´s choice arm than in the temsirolimus 
arms. A somewhat higher rate of infectious complica-
tions was noted in the temsirolimus treatment arms, 
though. Further side effects included anemia, asthe-
nia and gastrointestinal irritations.
Based on the results of this trial, temsirolimus has 
been approved for the treatment in the EU for patients 
with relapsed MCL.
Temsirolimus in combination therapy
Preclinical  studies  demonstrating  additional,  if  not 
even synergistic effects build a strong rationale for 
the use of a combination of temsirolimus with con-
ventional chemotherapy or monoclonal antibodies to 
improve the efficacy of single agent use.29 In detail, 
in vitro studies with rituximab showed an improved 
induction of apoptosis, complement-dependent cyto-
toxicity  (CDC)  and  antibody-dependent  cellular 
cytotoxicity (ADCC) in lymphoma cell lines.44–46 On 
the other hand, rituximab seems to inhibit the path-
way of extracellular signal-regulated kinase one and 
two  (ERK1/2)  and  thus  to  interact  with  the  PI3K 
pathway, the pathway also being altered by mTOR-
Inhibitors.47
Consequently, a phase II study was conducted to 
test  the  combination  of  temsirolimus  25  mg  once 
weekly  with  the  monoclonal  antibody  rituximab 
(375 mg/m², once weekly). Drugs were given weekly 
for 4 weeks during the first cycle, then continued with 
a weekly dose of temsirolimus and a single dose of 
rituximab every second 28 day cycle. If a response 
could  be  observed  after  6  cycles,  up  to  12  cycles 
were allowed. 71 patients with refractory or relapsed 
MCL were enrolled and 69 patients were available 
for analysis. The overall response rate was 59% with 
13   complete remissions (19%) and 28 patients with a 
partial response (41%).48
In  this  trial,  patients  with  rituximab-sensitive 
and  -refractory  disease  were  included,  and  appro-
priate cohorts were analyzed accordingly.49,50 Inter-
estingly,  in  contrast  to  studies  with  rituximab  in 
combination with conventional chemotherapy there 
was a smaller difference in response rates in respond-
ing patients between the two subgroups. The overall 
response rate in rituximab-sensitive patients was 63% 
(30 of 48) and 52% (11 of 21) for rituximab-refractory 
patients.48 Thus, we can assume that with this com-
bination at least a partial restoration of Rituximab 
efficacy in refractory patients might be reached. In 
general, treatment-related grade 3 or 4 adverse events 
resembled the data obtained in mono-therapy trials, 
and again thrombocytopenia in 16 patients (23%) and 
neutropenia in 15 patients (21%) were the dominant 
side effects. Additionally, fatigue in 14% and pneu-
monia in 10% were noted.41,42,48
Although a number of combination trials are pres-
ently ongoing, no data have been published on the 
various  trials  testing  mTOR  inhibitor-combos  yet. 
In brief, to date combinations of mTOR inhibitors 
like temsirolimus and everolimus have been tested 
in combinations with various chemotherapies (sin-
gle agent: bendamustine, cladribine or combination 
regimen:  CHOP,  FC),  immunomodulatory  agents 
(lenalidomide),  proteasome  inhibitors  (bortezomib) 
for MCL or MM or agents like PARP inhibitors or 
tyrosine kinase inhibitors like sorafenib, and it will 
be of great importance for the identification of opti-
mal combination partners to compare the results of 
the different trials. Currently ongoing trials are listed 
in Table 3.
Current standard of care for MCL  
and potential role for temsirolimus
In recent years, widely accepted standard options for 
patients with untreated MCL have been established. 
But still no general approach for the selection of a 
specific therapy for second-line treatment has been 
found. In suitable patients with poor risk features, 
allogeneic transplantation is frequently offered, and 
in patients with long lasting remissions after prior 
therapy, a more conservative approach is often used, 
e.g., a second line of chemoimmunotherapy. However, 
if  patients  experience  chemorefractoriness,  which Kirschey et al
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develops in a substantial proportion of patients, drugs 
functioning in an alternative way are attractive. Tem-
sirolimus and other agents are frequently used in this 
clinical situation and have shown promising activity. 
Their clinical use should be prioritized if no sufficient 
response lasting for more than 6–12 months after the 
last line of combination treatment can be achieved, 
if the patients have been exposed to active drugs like 
anthracyclines and cytarabinosid or if any contraindi-
cations to the use of chemotherapy are given.
Currently available data do not allow the conclusion 
that single agent use or the combination with antibodies 
are the ideal use of this drug, as clinical data are miss-
ing to evaluate their value in earlier line or in combina-
tion therapy. The stimulating data of the combination 
with rituximab are a first indicator for the advantages 
of a future combination use of this drug, and currently 
a number of trials are ongoing to evaluate various com-
binations. It will be exceedingly interesting to see the 
results e.g., for the combination with immunomodula-
tory agents like lenalidomide or proteasome inhibitors 
like bortezomib, which have been shown to be effective 
as single agents in MCL (Table 3).
Among  the  other  novel  agents  already  in  clini-
cal use, the effectiveness of bortezomib as a potent, 
selective and reversible inhibitor of the 26S protea-
some  has  been  presented  in  a  phase  II-trial.51  But 
also in combination with rituximab or combined with 
conventional chemotherapy promising response rates 
have been shown, with a good cytotoxic activity and 
acceptable toxicity in relapsed MCL. Currently, sev-
eral studies are going on that examine the use of bort-
ezomib in first-line treatment of MCL. Additionally, 
there are several immunmodulatory drugs, especially 
thalidomid and lenalidomide both of which are agents 
with anti-angiogeneic, anti-inflammatory and immu-
nomodulatory effective mechanism, with promising 
response rates in patients with relapsed MCL.2,22,52,53 
Results of trials evaluating different novel agents are 
summarized in Table 4. However, it has to be kept in 
mind, that there is a great variability in patient selec-
tion within all these trials.
Table 3. Ongoing clinical trials with treatments combining mTOR inhibitors in MCL.
Registration number Title combination type phase
NCT01076543 Lenalidomide and Temsirolimus  
in Treating Patients with Relapsed or 
Refractory Hodgkin Lymphoma  
or Non-Hodgkin Lymphoma
Immunomodulatory  
agent
2, recruiting
NCT01078142 Temsirolimus, Bendamustine and  
Rituximab for Relapsed Follicular  
Lymphoma or Mantle  
Cell Lymphoma
Chemotherapy  
and antibody
2, recruiting
NCT00787969 Rituximab, Cladribine, and  
Temsirolimus in Treating Patients  
with Newly Diagnosed Mantle  
Cell Lymphoma
Chemotherapy 
and antibody
2, recruiting
NCT01389427 Bortezomib, Rituximab, and  
Dexamethasone with or without  
Temsirolimus in Treating Patients  
with Untreated or Relapsed  
waldenstrom Macroglobulinemia  
or Relapsed or Refractory Mantle  
Cell or Follicular Lymphoma
Proteasome inhibitor,  
antibody and steroid
2, recruiting
NCT01381692 escalating Doses of Torisel  
in Combination with Three  
Chemotherapies Regimens:  
R-CHOP, R-FC or R-DHA for  
Patients with Relapsed/Refractory  
Mantle Cell Lymphoma (MCL).
Chemotherapy  
and antibody
2, not yet recruiting
NCT01281917 Study of velcade and Temsirolimus  
for Relapsed or Refractory  
Non-Hodgkin Lymphoma
Proteasome inhibitor 2, recruitingTemsirolimus for relapsed mantle cell lymphoma
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In addition, a great number of monoclonal anti-
bodies  is  currently  investigated  in  preclinical  and 
clinical trials. Thus, researches demonstrated prom-
ising  response  rates  and  long-term  remission  rates 
after  monotherapy  with  blinatunomab  in  patients 
with relapsed MCL,54 and Advani presented promis-
ing response rates after application of a combination 
therapy with inotuzumab-ozogamicin and rituximab.55 
Furthermore, drugs like PI3K inhibitors (CAL101), 
BTK inhibitors (PCI-32765) and Syk-inhibitors like 
fostamatinib have shown promising and sometimes 
impressive response rates. As reported, newer small 
molecules  like  the ATP-competitive  mTOR  kinase   
inhibitors (TKIs) bind to the ATP-binding site in the 
mTOR catalytic domain and inhibit both mTOR com-
plexes consecutively.56,57 They may be even more effi-
cient mTOR inhibitors. A combination of these drugs 
with and without chemotherapy and mTOR-inhibition 
seems attractive. However, the limited patient number 
combined with the number of available new agents 
requires a concerted action for the evaluation of these 
approaches.58 Importantly, overlapping toxicities may 
occur as well, and this requires the careful evaluation 
of potential combinations to avoid unnecessary com-
plications, and a careful selection seems advisable.
Use of temsirolimus in clinical practice
The elimination of temsirolimus and its metabolites 
happens mainly via faeces. The mean half-life of the 
main metabolite, sirolimus,59 is approximately four 
times longer than that of temsirolimus and increases 
with dose. The incidence of adverse events is particu-
larly correlated with the cumulative AUC.60 As the 
key enzyme in the metabolism is the cytochrome-
P450-isoform  CYP3A,  inhibitors  like  conazoles, 
HIV  protease  inhibitors  or  grapefruit  juice  can 
reduce the metabolizing function and the   resulting 
increased AUC  level.  On  the  other  hand,  CYP3A 
inductors like dexamethasone, AEDs or rifampicin 
may induce a faster metabolizing and elimination of 
temsirolimus and its metabolites, and Temsirolimus 
dose adjustment may be required to achieve sufficient 
drug levels.61 The typical side effect profile includes 
cytopenias,  asthenia  and  gastrointestinal  disorders, 
the last-mentioned can be reduced with preemptive 
treatment. In addition, one of the typical class effects 
of mTOR inhibitors is the induction of pneumonitis, 
and patients should be carefully evaluated if clinical 
symptoms suggest this diagnosis.
Today, the proven dose of 175/75 mg or the com-
bination with Rituximab seems to be a valid option 
associated with a substantial remission rate. It seems 
advisable,  even  though  we  have  no  corresponding 
prospective data, to use a lower than the approved 
starting dose in patients with severely compromised 
bone  marrow  reserve  in  order  to  avoid  treatment 
cessations.  In  this  context,  a  currently  active  trial 
is challenging the value of the 175 mg initial dose, 
testing the 175/75 mg regimen vs. a 75 mg regimen 
(NCT01180049).  Treatment  with  temsirolimus  is 
applied on a weekly basis, and in general given until 
disease progression or the occurance of unacceptable 
toxicyt. In case of CR an individualized treatment 
decision if how long treatment should be continued 
has to be made. To date there are only anecdotic data 
about a re-exposition to Temsirolimus after treatment 
cessation.
summary
Altogether, temsirolimus shows promising results in 
the therapy of patients with heavily pre-treated MCL, 
and especially responses in chemotherapy   refractory 
Table 4. Comparison of the activity of novel treatment approaches in relapsed MCL. Survival data in relapsed/refractory 
mantle cell lymphoma in comparison.
phase Med. pretx ORR pFs (months) TTp (months) Os (months) Literature
Temsirolimus (175/75) II–III 4 22% 4.8 4.8 12.8 43
Temsirolimus (175/25) II–III 4 6% 3.4 3.4 9.7 43
Bortezomib II 1* 33% 6.5 6.2 23.5 62
Thalidomide + Rituximab II 1 81% 20.4 n.a. 75% (estimated  
3 year survival)
52
Lenalidomide II 4 53% 5.6 6.5 n.a. 22
Flavopiridol II 1* 11% 21.9 n.a. 63
note: *Including untreated patients: med. pretx: median number of prior treatment lines.Kirschey et al
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patients underline its efficacy. Currently, the   evaluation 
of the combination of temsirolimus with other agents 
is under progress, in order to improve its efficacy and/
or promote the drug among the available treatment 
algorithms.
Thus, this period can be of great consequence for 
patients with mantle cell lymphoma, providing a great 
number of promising novel approaches to the treat-
ment of their disease, and the use of mTOR inhibitors 
has been one of the first successfully tested therapy 
approaches, broadening the armamentarium for the 
treatment of this challenging lymphoma subtype.
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